Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,891 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: St Louis, Missouri Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

NCT00001031
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 60 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 2:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

NCT01078636
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Jul 23, 2026, 2:20 PM EDT
Active, not recruiting No phase listed Observational

Multicenter Orthopaedics Outcomes Network for ACL Reconstructions

NCT00463099
View directory record Official record
Conditions
Rupture of Anterior Cruciate Ligament
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years to 80 Years
Enrollment
3,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2028
U.S. locations
8
States / cities
Boulder, Colorado • Iowa City, Iowa • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

NCT04176198
View directory record Official record
Conditions
Myelofibrosis
Interventions
Nusivertib, Ruxolitinib, Momelotinib
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

NCT06195930
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
Vericiguat (BAY1021189) 5 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Alexander City, Alabama • Richmond, Indiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Regadenoson in Sickle Cell Anemia

NCT01788631
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
10 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT07477639
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions
TRX319, Bendamustine
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Kansas City, Kansas • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting Phase 2 Interventional

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

NCT06855771
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BMS-986504
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
Anchorage, Alaska • Boise, Idaho • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Vaccine Uptake Trial

NCT05419232
View directory record Official record
Conditions
Vaccination Refusal, COVID-19
Interventions
Short Message Service (SMS) + Website Link Strategy, Phone Call with Peer Strategy
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
8
States / cities
Hazelwood, Missouri • Jennings, Missouri • Saint Ann, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Results available

Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses

NCT00305565
View directory record Official record
Conditions
Depression
Interventions
VNS Therapy
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
26
States / cities
Tucson, Arizona • Sacramento, California • Marietta, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting Phase 1 Interventional

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267
View directory record Official record
Conditions
Breast Cancer, Advanced Solid Tumor
Interventions
BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of M2951 in SLE

NCT02975336
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
42
States / cities
Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

NCT00878709
View directory record Official record
Conditions
Breast Cancer
Interventions
neratinib, placebo
Drug · Other
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
185
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 147 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 23, 2026, 2:20 PM EDT
Not listed Phase 2 Interventional

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

NCT04939116
View directory record Official record
Conditions
Glomerular Disease, Proteinuria
Interventions
ANG-3070, Placebo
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Birmingham, Alabama • Northridge, California • Vacaville, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Jul 23, 2026, 2:20 PM EDT
Completed No phase listed Observational

A Registry for Patients Taking Uptravi

NCT03278002
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jul 23, 2026, 2:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)

NCT06152237
View directory record Official record
Conditions
Rett Syndrome
Interventions
TSHA-102
Genetic
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
5 Years to 8 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
3
States / cities
Chicago, Illinois • Saint Paul, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 23, 2026, 2:20 PM EDT
Completed No phase listed Observational Results available

Development and Testing of a Pediatric Cervical Spine Injury Risk Assessment Tool

NCT05049330
View directory record Official record
Conditions
Cervical Spine Injury
Interventions
Not listed
Lead sponsor
Julie Leonard
Other
Eligibility
Up to 18 Years
Enrollment
22,444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Not listed Not applicable Interventional

ACCEL Absorbable Hemostat

NCT04728087
View directory record Official record
Conditions
Hemostasis
Interventions
ACCEL® Absorbable Hemostat Powder, Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01)
Device
Lead sponsor
Hemostasis, LLC
Industry
Eligibility
22 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Kansas City, Missouri • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

NCT00825734
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Sorafenib, Ixabepilone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
15
States / cities
Fort Myers, Florida • Terre Haute, Indiana • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2014 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Not applicable Interventional

Substance Abuse Treatment to HIV Care (SAT2HIV): The Implementation & Sustainment Facilitation Experiment

NCT03120598
View directory record Official record
Conditions
Substance Use
Interventions
ATTC strategy, ISF strategy
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
39
States / cities
Phoenix, Arizona • Claremont, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Jul 23, 2026, 2:20 PM EDT
Completed No phase listed Observational

Viral Pathogenesis of Early Cystic Fibrosis Lung Disease

NCT01973192
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 4 Months
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

NCT01241344
View directory record Official record
Conditions
Adenovirus Disease
Interventions
Brincidofovir, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
3 Months to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Reducing Depression in Dementia Caregivers

NCT00056316
View directory record Official record
Conditions
Depression
Interventions
Basic Education, Behavioral Skills Training: Experimental
Behavioral
Lead sponsor
University of Missouri, St. Louis
Other
Eligibility
50 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2014 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

NCT04043806
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Jul 23, 2026, 2:20 PM EDT